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ABSTRACT 
 
Aims: Metabolite levels can be measured non-invasively using in vivo 1H Magnetic Resonance 
Spectroscopy (MRS). These tumour metabolite profiles are highly characteristic for tumour type in 
childhood brain tumours, however the relationship between metabolite values and conventional 
histopathological characteristics has not yet been fully established. This study systematically tests 
the relationship between metabolite levels detected by MRS and specific histological features in a 
range of paediatric brain tumours. 
Methods: Single voxel MRS was performed routinely in children with brain tumours along with 
the clinical imaging prior to treatment. Metabolites were quantified using LCModel. Histological 
features were assessed semi quantitatively for 27 children on H&E and immunostained slides, 
blind to the metabolite values. Statistical analysis included two-tailed independent samples t-tests 
and two-tailed Spearman-rank correlation tests.  
Results: Ki67, cellular atypia and mitosis correlated positively with choline metabolites, 
phosphocholine in particular. Apoptosis and necrosis were both associated with lipid levels, with 
the relationship dependant on the use of long or short echo time MRS acquisitions.  Neuronal 
components correlated negatively and glial components positively with N-acetyl-aspartate. Glial 
components correlated positively with myoinositol.  
Conclusion: Metabolite levels in children’s brain tumours measured by MRS are closely 
associated with key histological features routinely assessed by histopathologists in the diagnostic 
process. This further elucidates our understanding of this important non-invasive diagnostic tool 
and strengthens our understanding of the relationship between metabolites and histological 
features.  
 
Keywords: Magnetic Resonance Spectroscopy; paediatric brain neoplasms; histology, ki67, 
necrosis, apoptosis, metabolites, lipids 
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INTRODUCTION  
 
Conventional Magnetic Resonance (MRI) provides structural information on tumour location and 
properties, however it provides little information on the biological properties of the tumour. 
Increasingly, MR methods are being developed that provide complementary biological information 
in additional to standard structural information. 1H Magnetic Resonance Spectroscopy (MRS) is a 
technique that measures tumour metabolite profiles and these have been shown to provide a 
powerful non-invasive characterization of children’s brain tumours [1-4]. Clinically, tumour type is 
currently categorized by histopathology [5], which is the acknowledged standard against which 
non-invasive techniques are compared [1]. Thus, there is a need to determine how metabolite 
biomarkers obtained using MRS relate to established histopathological characteristics [6], and to 
further understand the relationship between non invasively determined metabolite profiles and 
tumour biology. 
 
In vivo MRS is increasing being used as a non-invasive method of measuring metabolites for 
disease monitoring in many brain disorders including neurodegenerative diseases such as 
Alzheimer’s and Parkinson’s disease, traumatic brain injury, psychiatric disorders, and 
neurooncology [2,7-12]. A growing number of studies are investigating the value of MRS for both 
diagnostic classification and post-treatment monitoring in brain tumours [4,13-16]. However, 
whilst some studies have correlated clinical information such as tumour grade with MRS features, 
there are relatively few studies that have directly examined the relationship between in vivo 
metabolite markers and traditional histopathological measures [17-21]. Even fewer studies have 
been undertaken in paediatric brain tumour patients [22,23]. There is also an increasing trend in 
clinical studies towards the use of short echo time MRS data which can measure a larger number 
of metabolites, increasing the information available and allowing detailed laboratory findings to be 
investigated [24-26].  
 
The most commonly investigated metabolites in the in vivo MRS of brain tumours are N-acetyl 
aspartic acid (NAA), total choline, creatine, lipids, myoinositol, glycine, taurine, glutamate and 
glutamine [4,26]. Perhaps the most evidence for an association between MRS and histology is for 
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the choline metabolites which have been linked to cell density [27,28], Ki67 proliferation index 
[18,19] and nuclear shape [17,27], as well as being suggested as a marker of rapid cellular 
proliferation and tumour aggressiveness [23,29,30]. There is also a substantial literature on lipid 
levels detected by MRS in tumours. Lipids detected by MRS reside in intracytoplasmic lipid 
droplets which increase greatly in apoptosis and necrosis [31]. Very high lipid levels are detected 
by MRS in necrotic tumours and this has been used as an indicator of grade in adults with 
gliomas [31,32]. However, extensive necrosis is rarer in childhood brain tumours and the 
association with MRS detectable lipids has not yet been established fully. MRS lipids have also 
been linked to Ki67 although this is most likely to be through an association between necrosis 
and grade [27].  
 
Myoinositol, which can be detected reliably by short echo time MRS, is a cerebral osmolyte and 
has been proposed as a marker of astrocytes and gliosis [26,33]. Elevated myoinositol has also 
been shown to distinguish between grade in astrocytoma [34,35]. Tumour cells in astrocytic 
neoplasms stain intensely with antibodies to GFAP [36] however myoinositol in tumours has not 
yet been linked convincingly to this. Glycine has been detected in paediatric brain tumours in vivo 
by Davies et al.[37] and shown to be significantly higher in high grade vs. low grade tumours. N-
acetyl-aspartate (NAA) is commonly regarded as a neuronal marker as it has been found to be 
preferentially highly expressed in neurons rather than glial cells [38]. In addition, in vivo MRS of 
normal brain displays a prominent NAA peak, whilst tumours display far less [21,26,39,40]. 
However, significant amounts of NAA are found in pilocytic astrocytomas,[40] and its origin in 
these tumours remains controversial. In diffuse tumours it may arise from normal brain.  
 
Despite the increasing use of MRS as a valuable clinical diagnostic and prognostic tool in brain 
tumours, there are still very few studies that have investigated the specific relationships between 
metabolites detected with in vivo MRS and traditional histopathological features. As metabolites 
have been proposed as potential biomarkers, further investigation of their relationship to 
traditional histological measures is essential for the validation of their biomarker value. We have 
examined the relationship between key metabolites in vivo and common histopathological 
features in a range of paediatric brain tumours at both long and short echo time. The increasing 
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emergence of robust clinical in vivo MRS as an important diagnostic and prognostic technique 
makes this study timely, particularly for paediatric patients where non-invasive methods are highly 
valued. 
 
PATIENTS & METHODS 
 
Magnetic Resonance Spectroscopy (MRS) 
MRS was performed routinely on a 1.5T MRI Scanner (Siemens Symphony or General Electric 
Signa Excite) in children with brain tumours combined with their clinical imaging at Birmingham 
Children’s Hospital (BCH) from 2003 to 2009.  MRS was carried out prior to any treatment 
(except stereotactic biopsy) and all analysis was undertaken retrospectively. Informed parental 
consent was obtained for the use of patient data for research purposes and ethical approval for 
the study was granted by the local research ethics committee (Derby NRES Committee). The 
acquisition protocol involved using point-resolved spectroscopy (PRESS) localization for a single 
voxel. The voxel volume was either 3.375cm3 or 8cm3 according to the size of the tumour.  A TE 
of 30ms was used for all patients. Some patients also had long echo time (TE=135) MRS 
acquired (n=8). The repetition time was 1500ms and 128 repetitions were used for 8cm3 voxels 
while 256 repetitions were used for 3.375 cm3 voxels. A water unsuppressed MRS was acquired 
for eddy current correction and as a concentration reference. Raw MRS signal data and voxel 
position images were transferred to a dedicated computer network. The raw MRS signal was 
processed using LCModel software (Version 6.2.0)[41], which determines metabolite 
concentrations by fitting the data to a linear combination of basis functions formed from individual 
metabolite spectra. The unsupressed water signal was used as a concentration reference. 
Concentration values were calculated assuming a tissue water concentration of that for white 
matter. Lipid concentrations are reported per proton. An example showing metabolite fitting in 
LCModel in a brain tumour case from this cohort is presented in figure 1. Cramer-Rao Lower 
Bounds (CRLB) are also determined by LCModel, and these indicate the accuracy with which the 
metabolite concentrations have been estimated. Metabolites and lipids with CRLB less 30% were 
accepted for accurate quantification. 
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The spectra were reviewed individually to assess quality, and the ones failing the criteria set were 
excluded from the analysis. These criteria included signal-to-noise ratio (S/N) ≥ 6 and full-width 
half-maximum (FWHM) ≤ 0.15ppm. Baseline stability, good phasing, adequate water suppression 
and absence of artefacts were assessed by inspection. The voxel positioning was also reviewed 
to ensure the voxel was positioned over tumour and did not include large amounts of normal 
brain or cyst. In addition, voxels needed to be at least 3mm away from lipid-containing bone and 
scalp.    
 
Segmentation 
For patients with significant amounts of cyst or ventricle in the voxel, segmentation of the T1 (pre 
and post contrast) and T2 MR images was performed and the metabolite concentrations adjusted 
accordingly (corrected metabolite concentration = concentration in voxel/active tumour fraction in 
voxel). The concentration of lactate was not altered in the three patients with cyst in the voxel (the 
tumour cysts contain lactate), but was altered for the patient with ventricle in the voxel.   
 
Histological review 
Retrospective histological review of H&E stained sections obtained at the time of biopsy or 
tumour resection for each patient was undertaken jointly between EO and MAB, blind to the MRS 
results. A single H&E stained section was prepared for each paraffin block. The slides assessed 
were representative of the tumour diagnosis and grade for all cases included in the study. The 
assessment was semi-quantitative, with each feature assigned a category. The H&E stained 
slides were assessed (with the scoring categories detailed in Table 1) for architecture and 
cellularity, presence of cellular atypia, mitosis, apoptosis and necrosis. Architecture was defined 
as tumour tissue with a structure that was either solid, diffuse, cystic or a combination of each. 
Atypia denotes the degree of abnormality within a tumour based on degree of alteration of shape 
and size of cells and nuclei compared to normal cells. Mitotic figures were defined as darkly 
stained elongated structures indicating chromosomes condensing and duplicating. Apoptotic cells 
were identified as cells with condensing and fragmenting chromatin (stained blue), often also with 
an irregular shape and size, as described previously[42]. Necrosis was scored as the presence or 
absence of tissue areas with cell shrinkage and pronominally eosinophilic stain (stained pink) 
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indicating DNA breakdown from dead or dying cells. Also recorded was the presence of 
neoplastic glial elements, reactive glial elements, entrapped neuronal elements, lesional neuronal 
elements (rosetting), and vascularity. Ki67, GFAP and synaptophysin immunohistochemical 
stains were also reviewed where available, the number of patients where this information was not 
available is detailed in table 1.  
 
Statistical analysis between metabolite levels and histopathological features was undertaken in 
SPSS v.17.0, using two-tailed independent samples t-tests and Spearman-rank correlation tests. 
P-values of <0.05 were considered statistically significant. 
 
 
RESULTS 
 
Twenty-seven children with brain tumours were included in the study. The breakdown by tumour 
type (according to WHO 2007)[5] was: 9 medulloblastomas,  5 pilocytic astrocytomas, 3 
ependymomas, 2 atypical teratoid/rhabdoid tumours, 2 glioblastoma, 2 diffuse astrocytomas, 2 
dysembryoplastic neuroepithelial tumours, 1 pineoblastoma, 1 gliomatosis cerebri. The categories 
of all histopathological variables and the respective number of patients in each are shown in 
Table 1. Representative microphotographs of the key histopathological parameters assessed are 
shown in figure 2.  Statistically significant correlations are summarized in Table 2.  
 
Tumour proliferation measured by the percentage of Ki67 nuclear staining correlated positively 
with phosphocholine (PCh) and glycerophosphocholine+phosphocholine (GPC+PCh, fig. 3c) but 
not GPC. Apoptosis correlated positively with lipids+macromolecules (fig. 2) and taurine (Tau, fig. 
3b), p<0.02.  For the cases where necrosis was absent (n=18) statistically significant positive 
correlations were found between apoptosis and lipids/macromolecules at 0.9ppm (rs=0.645), 
1.3ppm (rs=0.656), 2.0ppm (rs=0.718) and 1.3/0.9 ppm (rs=0.667), p<0.005. Taurine was also 
significantly correlated with apoptosis in the non-necrotic patients,  rs = 0.668, p = 0.002. 
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A  comparison between the necrotic (n=8) and non-necrotic tumours (n=18), found no statistically 
significant differences with respect to the amount of lipids+macromolecules at 0.9, 1.3 and 
2.0ppm or lactate. However, long TE total lipids+macromolecules were found to be significantly 
higher in the group with necrosis (n=2) compared to the group without necrosis (n=6), p<0.05. 
Lipids at 1.3/0.9 were not significantly different between these groups. Apoptosis did not 
significantly correlate with lipids/macromolecules at long TE. 
 
There was a significant positive correlation between atypia and PCh, GPC+PCh and 
lipids+macromolecules. A scatter plot of atypia vs. lipids+macromolecules at 2.0ppm is shown in 
fig. 3d. Mitosis also correlated positively with PCh, and lipids+macromolecules, but not with GPC 
or GPC+PCh. Lesional neuronal elements correlated negatively with N-Acetyl aspartate (NAA) 
and N-Acetyl aspartate+N-Acetylaspartylglutamate (NAA+NAAG). No significant difference in 
NAA or NAA+NAAG between patients with and without entrapped neuronal elements was found. 
Neoplastic glial elements correlated positively with myoinositol (mIns, fig. 3e), NAA, NAA+NAAG, 
and negatively with glycine (Gly, fig. 3f), but not with mIns+Gly together. The concentrations of 
mIns, Gly, mIns+Gly, NAA and NAA+NAAG were not significantly different between groups where 
reactive glial elements were present (n=15) or absent (n=12), p>0.07. GFAP correlated 
negatively with Gly, p< 0.003, but there was no significant correlation with mIns.   
 
The vascularity and architecture of the tumours did not significantly correlate with lactate, and 
synaptophysin staining was not significantly correlated with NAA and NAA+NAAG. However, it 
should be noted that synaptophysin staining was not performed on 16 patients as it is not 
undertaken in tumours that are expected to be negative e.g. in glial tumours. 
 
There were also several significant correlations between tumour grade and metabolite 
concentration, in particular for PCh, lipids+macromolecules, creatine, taurine, and glycine which 
were all positively associated with increasing grade (Table 3). In contrast, NAA+NAAG was the 
only metabolite with a significant negative association with increased grade, p < 0.001 (Table 3). 
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DISCUSSION  
 
MRS has seen increasing use as a non-invasive tool for the characterization and monitoring of 
brain tumours. Although many studies have reported the relationship between metabolites and 
diagnostic groups, tumour aggressiveness, and prognosis, few have addressed the relationship 
with histopathological features routinely assessed after biopsy or resection. In particular, there is 
a lack of studies systematically comparing the set of major morphological features assessed in 
routine histopathology with MRS acquired in a manner which maximizes the number of 
metabolites quantified. This study has found important associations between metabolites 
detected by in vivo MRS in paediatric brain tumours and key histological features including 
apoptosis, necrosis, mitosis, atypia, glial and neuronal components.  
 
Total choline was found to correlate positively with Ki67. Choline containing metabolites are 
involved in membrane synthesis and have a role in membrane turnover[30]. Total choline 
elevation is thought to be a marker of malignant transformation and rapid cellular proliferation as 
a result of increased mitosis, leading to an abnormal increase in metabolism [17,18,43,44]. 
Previous studies have identified a correlation between Ki67 and total choline in a variety of 
tumours including grade II-IV astrocytomas in adults [19]; medulloblastomas in children [23,45] 
and homogeneous, but not heterogeneous, gliomas in adults [18]. Two other studies in adult 
gliomas did not find a correlation between total choline and Ki67 [27,28]. The reason for these 
conflicting results has been postulated to be that phosphocholine and glycerophosphocholine 
both contribute to total choline but it is the ratio phosphocholine/glycerophosphocholine which is 
related to tumour growth [46,47]. In the current study, a positive correlation was found between 
Ki67 and phosphocholine but not glycerophosphocholine, supporting this assertion. In addition, 
both atypia and mitosis, also features of tumour aggressiveness, had significant correlations with 
phosphocholine, although only atypia correlated with total choline. The determination of PC and 
GPC by 1H MRS at 1.5T in vivo is far less robust than for tCho and results for these metabolites 
should be interpreted with caution. There is some evidence that values for PC and GPC from 1H 
MRS at 1.5T reflect those seen in these tumours [1,47,48] and so we have included them here for 
completeness. Recent evidence has began to link underlying patterns of gene expression to in 
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vivo and ex vivo choline metabolism in breast cancer sub-groups [49,50]. This further emphasises 
the importance of the choline metabolites as biomarkers in all tumours.  Our work suggests that 
choline metabolism may play an important role in cellular proliferation and membrane turnover of 
paediatric brain tumours, thus warranting continued investigation.  
 
Atypia and mitosis were found to have significant correlations with lipids in the current study. 
Lipids measured by MRS are known to be higher in more aggressive tumours and associated 
with poor survival [14,51]. Lipids have also been associated with apoptosis [31,52,53], an active 
process of programmed cell death during which large intracellular lipid droplets accumulate that 
are detected by MRS [54,55]. High lipids were associated with necrosis as well as apoptosis and 
this association was dependant on the MRS technique used to acquire the data. Lipids measured 
by short echo time MRS correlated with apoptosis whereas lipid concentrations measured by long 
echo time MRS were higher in the necrotic tumours. Short echo time MRS is very sensitive for 
the detection of lipids and it is likely that this is important in detecting the signals from the small 
lipid droplets which experience some motion restriction of the fatty acid chains [54]. The less 
sensitive long echo time MRS is well suited to detecting the large levels of more mobile lipid 
associated with necrosis. Prior associations between lipid and necrosis have largely been carried 
out with long echo time data [31,56]. The current findings suggest that altering MRS technique 
between short and long echo time sequences may be useful for elucidating the relative 
contribution of lipid arising from apoptosis and necrosis respectively, although further work will be 
required to conclusively determine this. 
 
Taurine was also found to be positively correlated with apoptosis although there is less 
information in the literature regarding this association. Ex vivo tissue metabolite analysis and 
histopathological analysis performed by Opstad et al. found taurine to significantly correlate with 
apoptotic cell density in necrotic and non-necrotic biopsies of adult gliomas [57]. In a model of 
apoptotic death in cultured cerebellar granule neurons, taurine was found to be implicated in cell 
shrinkage during apoptosis [58]. In further support of this, Lang et al.,[59] loaded Jurkat human T-
lymphocytes with [3H]taurine and were able to induce apoptotic cell death. The resulting taurine 
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release coincided and presumably contributed to the cell shrinkage typical of apoptotic death, and 
preceded DNA fragmentation.  
 
Although NAA is commonly regarded as a putative neural marker and a measure of neural 
density and function, its origin in tumours is less certain with prior evidence having found  
prominent NAA peaks in tumours of astrocytic origin[19,45,60]. Interestingly, we found a 
significant positive correlation between NAA and neoplastic glial elements and a significant 
negative correlation between NAA and lesional neuronal elements. As the NAA was most 
prominent in the pilocytic astrocytomas, this result supports the assertion that NAA seen in these 
tumours arises from tumour tissue, rather than from neurons entrapped within the tumour [61,62]. 
Furthermore, scrutiny of the voxel positions confirms that the NAA cannot be explained by normal 
appearing brain from within or close to the voxel. The origin of NAA in astrocytoma cells may be 
linked to O-2A progenitor cells which contain NAA [40,63]. These cells are precursors of type-2 
astrocytes, and some low grade astrocytomas express antigens consistent with type-2 astrocytic 
lineage [64].  
 
Myoinositol (mIns) was found to correlate positively with neoplastic glial elements, consistent with 
studies which have shown mIns to be high in glial tumours and a potential astrocytic marker 
[9,34,35,45,60]. There was no correlation between mIns and GFAP expression, although they are 
both considered to be markers of glial differentiation. This is in agreement with Oz et al [65]., who 
investigated GFAP levels in the CSF of patients with spinocerebellar ataxia type 1 and their 
relationship to metabolites from different brain locations. The lack of correlation between GFAP 
and mIns is perhaps unsurprising given that GFAP histological expression can be highly variable 
in astrocytic tumours [66]. 
 
In this study lactate was not found to correlate with tumour architecture, necrosis or vascularity. 
Although some studies have reported an association between lactate and tumour necrosis, 
others have detected very little correlation between lactate and histological tumour properties 
[21,44,67-69]. It is likely that lactate detected in vivo in brain tumours is a measure of abnormal 
metabolic activity, and not exclusively linked to tumour necrosis. The significant association 
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between between tumour grade and individual metabolites such as total choline, phosphocholine, 
lipids and macromolecules, glycine, and taurine is also consistent with prior work, with elevated 
levels of these metabolites previously reported in high grade brain tumours[14,37,45,47,70]. An 
association between increased NAA in low grade glial tumours has also been previously 
indentified [71].  
 
As metabolite profiles are increasingly being used to both classify and monitor disease 
progression in paediatric brain tumours, it is important to examine the association between such 
metabolites and traditional histological markers. This will aid in the interpretation of MRS 
metabolite measures in tumours, as well as increasing our understanding of the biological 
underpinnings of metabolites as potential biomarkers of disease. Metabolites also add additional 
information beyond that associated with diagnosis alone, including prognostic information useful 
for risk stratification, monitoring relapsed tumours which are rarely re-biopsied and examined 
histologically, and for distinguishing relapse from treatment related effects which would otherwise 
be very difficult using conventional MRI. Furthering our understanding of the relationship between 
histology and metabolites in resected brain tumours will also aid in the interpretation of MRS in 
cases where biopsy and/or resection is not routinely undertaken. 
 
In summary, we have tested the association between metabolite levels determined by in vivo 
MRS and routinely assessed histopathological features in paediatric brain tumours. The results 
confirm previous findings from in vitro and animal studies. Previous in vivo clinical studies have 
been restricted to the investigation of a small number of metabolites investigated in gliomas in 
adults. In vivo MRS is a powerful non-invasive method for the characterization of paediatric brain 
tumours and gives information which correlates well with important histopathological features 
such as proliferation index, apoptosis and necrosis. Larger multicentre studies in the paediatric 
population will enable these correlations to be tested in specific tumour types.  
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Table 1. Histopathological categories and respective number of patients (short TE studies)  
 
Histopathological 
feature 
Categories Number of patients 
Ki67 
<1% 7 
1-2% 2 
4-10% 1 
>10% 14 
Not performed 3 
Apoptosis 
None 4 
Very low or low 10 
Moderate 7 
Moderate to high or high 6 
Necrosis Present 9 (1 very localised) 
Absent 18 
Cellular Atypia 
None 3 
Very low or low 8 
Low to moderate or low focally moderate or moderate 8 
High 8 
Mitosis 
None 7 
Very low or low 7 
Moderate 7 
High 5 
Indeterminate 1 (removed from analysis) 
Lesional Neuronal 
Elements 
None 13 
Focally PNET-like 3 
Neuronal Rosettes 4 
Widespread PNET-like 7 
Entrapped Neuronal 
Elements 
Present 3 
Absent 24 
Neoplastic Glial 
Elements 
None 10 
Focally or entrapped 2 
Predominantly glial 15 
Reactive Glial 
Elements 
Present 15 
Absent 12 
GFAP staining 
Negative 2 
Very focal or reactive glial 6 
<10% 2 
10-50% 4 
>50% 11 
Not performed 2 
Vascularity 
Low 8 
Moderate 14 
High 3 
Indeterminate 2 
Architecture 
Solid 15 
Solid diffuse 6 
Solid occasionally microcystic or microcystic 3 
Half solid half cystic 3 
Synaptophysin 
staining 
Negative 1 
Scattered positive cells 1 
Focally positive 3 
Positive 6 
Not performed 16 
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Table 2. Summary of statistically significant correlations between histopathological features 
and metabolites detected by 1H MRS.  
 
Feature Metabolite Correlation/t-test* p-value 
Ki67  
PCh +ve 0.031 
GPC+PCh +ve 0.006 
Apoptosis  
Lip+MM  at 0.9, 1.3, 2.0, 
1.3/0.9 ppm +ve 
0.001, 0.003, 
0.005, 0.001 
Tau +ve 0.014 
Necrosis  Long TE Lip+MM at 0.9, 1.3, 2.0 ppm 
Higher - group with 
necrosis 0.002, 0.002, 0.004 
Cellular atypia  
PCh +ve 0.013 
GPC+PCh +ve 0.014 
Lip+MM at 0.9, 1.3, 2.0 ppm +ve 0.023, 0.016, 0.002 
Mitosis  
PCh +ve 0.004 
Lip+MM at 0.9, 1.3, 2.0 ppm +ve 0.006, 0.012, 0.001 
Lesional neuronal 
elements  NAA, NAA+NAAG -ve <0.0001 
Neoplastic glial 
elements  
mIns +ve 0.024 
Gly -ve 0.001 
NAA, NAA+NAAG +ve <0.0001 
GFAP  Gly -ve 0.003 
 
*  “+ve” refers to a positive correlation and “-ve” refers to a negative correlation 
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Table 3. Summary of statistically significant correlations between metabolites detected by 1H 
MRS and tumour grade. 
 
Metabolite 
Spearmans 
correlation 
coefficient 
Direction of 
correlation* p-value 
Creatine 0.397 +ve 0.05 
PCh 0.571 +ve 0.001 
GPC+PCh 0.626 +ve 0.001 
Gly 0.566 +ve 0.001 
Lip+MM at 0.9, 1.3, 2.0 
ppm 0.617 +ve 0.001 
Lip 1.3/0.9 0.43 +ve 0.05 
Tau 0.39 +ve 0.05 
NAA+NAAG 0.636 -ve 0.001 
 
Low grade 1, n = 8; Intermediate grade 2/3, n = 6; high grade 4, n = 13 
*  “+ve” refers to a positive correlation and “-ve” refers to a negative correlation 
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Figure Legends 
 
Figure 1. Example MRS spectra of a medulloblastoma tumour acquired at short (TE=30) echo 
time. A, B= Conventional T1 weighted MRI images showing tumour in the cerebellum. The 
position of the voxel for acquiring MRS data is indicated by the white box. C= Corresponding 
MRS spectra with key metabolites identified and fitted in LC model.  Abbreviations are labelled as 
follows: Gly (glycine), mIns (myoinositol), Tau (taurine), MM (macromolecules), ppm(parts per 
million).  
 
Figure 2. Representative microphotographs illustrating pathological parameters assessed 
semiquantitatively. A= Classical medulloblastoma (H&E, x40 original magnification) showing a 
high cellularity and high levels of apoptosis (*), B= Pilocytic astrocytoma (H&E, original 
magnification x20) showing a low cellularity, and a partly solid, partly cystic (*) architecture, C= 
Classical medulloblastoma with synaptophysin widely and strongly expressed in tumour cells. 
Synaptophysin is a specific marker for tissue derived from neural and neuroendocrine tissue, and 
positivity is indicated by brown labelling within cell cytoplasm and membranes. D= Classical 
medulloblastoma with high Ki67 labeling (>50% positive). Positive Ki67 staining is represented by 
the brown nuclear staining which is a specific marker of proliferating cells. E= Pilocytic 
astrocytoma showing strong staining with GFAP, an intermediate filament protein that labels 
astrocytic and some ependymal cells within the central nervous system. GFAP expression is 
indicated by brown membranous and cytoplasmic staining of tissue. 
 
Figure 3.  Plots showing mean metabolite concentration (mM) across categories for each 
histological feature,  A= mean macromolecules (MM) 09+Lip09 vs Apoptosis, B= mean Tau vs 
apoptosis, C= mean GPC+PCh vs Ki67, D= mean MM20+Lip20 vs Atypia, E= mean mI vs 
Neoplastic glial elements, F= mean Gly vs Neoplastic glial elements. MM09+Lip09=lipids and 
macromolecules at 0.9ppm, Tau=taurine, GPC=glycerophosphocholine, PCh=phosphocholine, 
MM20+Lip20= lipids and macromolecules at 2.0ppm, mI=myo-inositol, Gly=glycine. Error bars 
represent +/- 1 standard error.  
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